CAPR Stock Surges As FDA Keeps Duchenne Pathway Alive

Capricor Therapeutics Inc. stocks have been trading up by 13.75 percent after promising biotech progress boosted investor optimism.

Live Update At 12:32:17 EDT: On Monday, August 24, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 13.75%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CAPR has traded like a biotech rollercoaster this month. The daily chart shows Capricor Therapeutics pinned near $4 ahead of its Q2 2026 update, then exploding to intraday highs above $8 on 2026/08/14 after the FDA and Cantor news. Even after some giveback, CAPR recently closed near $7.16, almost double where it sat just weeks ago.

Intraday, CAPR’s 5‑minute tape on the latest session shows aggressive opening volatility — a spike from $8.03 down into the mid‑$6 range, then a grind back toward $7.20. That’s classic momentum‑name trading: wide ranges, heavy liquidity, and plenty of chances for both breakout and fade setups.

Fundamentally, Capricor Therapeutics remains pre‑revenue. Q2 2026 income statements show a net loss of about $40.7M, with research and development running roughly $28.9M and G&A about $14.1M. Cash and marketable securities of roughly $237.9M give CAPR a comfortable current ratio of 7.4 and working capital over $200M. The flip side is a deeply negative return on equity and cash flow, signaling persistent burn. For traders, that mix — strong balance sheet, no revenue, binary catalyst — defines CAPR as a pure event‑driven biotech play.

Why Traders Are Watching CAPR’s Momentum

The real spark for CAPR was the regulatory twist around deramiocel. After a 9–3 negative advisory committee vote on the original cardiomyopathy indication, many traders wrote Capricor Therapeutics off as just another failed biotech. Then the FDA said it is willing to review an amended BLA that leans on 24‑month HOPE‑3 extension data and sharper analyses, refocusing deramiocel on upper‑limb skeletal muscle function in Duchenne muscular dystrophy. That single line from the agency flipped the story from “door closed” to “door still open, but narrower.”

The market reacted instantly. CAPR shares ripped more than 80%, at one point up roughly 104% in premarket on 2026/08/14 as traders crowded into the name. The HOPE‑3 Phase 3 trial had already hit its primary upper‑limb endpoint and landed in The Lancet, so the data backdrop was there. The FDA’s openness to a narrower label just gave that data a path.

Layer on Cantor Fitzgerald’s move, and you get fuel on the fire. The upgrade from Neutral to Overweight and the price‑target hike from $3.50 to $28 — well above the prior mean target near $26.12 — signaled that at least one major shop now sees serious upside if deramiocel clears the hurdle. CAPR went from forgotten to front‑burner almost overnight.

At the same time, Capricor Therapeutics is tightening its focus. Non‑deramiocel programs are largely paused, commercial spending is moderated pending clarity, and a distribution dispute with NS Pharma is headed to arbitration. That makes CAPR even more binary: deramiocel and the FDA path matter more than anything else on the story.

Add in a new Schedule 13G showing a sizable passive stake and the Kaos Capital letter pushing for board changes, strategic alternatives, and cash preservation, and CAPR becomes a classic catalyst stew. Regulatory headlines, analyst calls, activist pressure, and potential M&A chatter — these are exactly the ingredients momentum traders hunt.

Conclusion

For active traders, CAPR now sits at the crossroads of science, regulation, and strategy. Capricor Therapeutics has late‑stage data that works, a lead asset deramiocel still under active FDA review, and a sell‑side upgrade that took the price target to $28. It also has no revenue, a widening loss, and a story concentrated almost entirely in one Duchenne program, with an NS Pharma dispute and legal overhangs adding background noise.

The balance sheet gives CAPR time. Management says its roughly $238M in cash, cash equivalents, and marketable securities can fund operations for at least 12 months under current plans. That helps cap near‑term dilution worries, but it does not erase the binary nature of the next FDA steps. Any extension of the PDUFA date buys runway but also stretches headline risk, which can keep volatility elevated.

For short‑term traders who live on volatility, that is not a bug, it is the feature. CAPR’s recent range — doubling off the lows, intraday swings of more than $1 — offers both opportunity and trap doors. The key, as always in these speculative biotech names, is discipline. As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. In Tim Sykes’ words, “Volatility is your best friend and worst enemy at the same time — study the catalyst, know your levels, and never risk blowing up on one play.” Capricor Therapeutics now fits that playbook perfectly: a high‑reward, high‑risk catalyst stock that demands strict rules and fast cuts when the tape turns.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks